Azithromycin for Child Survival in Niger: Delivery Trial (AVENIR)
Primary Purpose
Mortality, Child Health, Implementation
Status
Recruiting
Phase
Phase 4
Locations
Niger
Study Type
Interventional
Intervention
Azithromycin for Oral Suspension
Sponsored by

About this trial
This is an interventional treatment trial for Mortality
Eligibility Criteria
Inclusion Criteria:
At the community-level, eligibility includes:
- Location in one of the 80 Dosso communities randomly selected for the delivery trial
- Population 250 to 2,499*
- Distance > 5 km from the district headquarters town
- Verbal consent of community leader(s)
At the individual-level, eligibility includes:
- Age 1-59 months
- Primary residence in a study community
- Verbal consent of caregiver/guardian for study participation
- Weight ≥ 4 kg
Exclusion Criteria:
At the community-level, eligibility includes:
- Inaccessible or unsafe for study team
- "Quartier" designation on national census *Population size as estimated from the most recent national census or projections
At the individual-level, eligibility includes:
• Known allergy to macrolides
Sites / Locations
- Program National de Santé OculaireRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Azithro 1-59 fixed point
Azithro 1-59 door-to-door
Arm Description
Azithromycin distribution to children 1-59 months of age using a fixed-point delivery approach via existing community health workers
Azithromycin distribution to children 1-59 months of age using a door-to-door delivery approach via existing community health workers
Outcomes
Primary Outcome Measures
Treatment Coverage
Treatment coverage as defined by the number of doses of azithromycin administered in each community divided by the total eligible population
Secondary Outcome Measures
Program Costs
Program costs as captured by routine administrative data collection during the study period and by micro-costing activities
Fidelity of intervention rollout
Fidelity of intervention rollout reported as the percent of protocol steps with complete adherence by the field team
Acceptability of intervention
Participant and provider perception of acceptability of delivery approaches as measured by surveys conducted post-distribution
Full Information
NCT ID
NCT04774991
First Posted
February 24, 2021
Last Updated
September 18, 2023
Sponsor
University of California, San Francisco
Collaborators
Bill and Melinda Gates Foundation, Programme National de Santé Oculaire, Ministère de la Santé Publique du Niger
1. Study Identification
Unique Protocol Identification Number
NCT04774991
Brief Title
Azithromycin for Child Survival in Niger: Delivery Trial
Acronym
AVENIR
Official Title
Azithromycin for Child Survival in Niger: Delivery Trial
Study Type
Interventional
2. Study Status
Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 28, 2021 (Actual)
Primary Completion Date
November 2024 (Anticipated)
Study Completion Date
November 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of California, San Francisco
Collaborators
Bill and Melinda Gates Foundation, Programme National de Santé Oculaire, Ministère de la Santé Publique du Niger
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This cluster-randomized trial aims to compare the impact of different delivery approaches to azithromycin distribution on coverage, costs, and feasibility outcomes. The investigators hypothesize that door-to-door delivery will have higher coverage and costs and similar feasibility and acceptability compared to fixed-point delivery.
Detailed Description
Azithromycin distribution has been shown to reduce mortality in children 1-59 months. This trial aims to contribute evidence on viable approaches to implementation as high mortality countries consider this intervention to improve child survival. From a pool of eligible rural and peri-urban communities in the Dosso Region in Niger, 80 will be randomly selected and randomized to receive door-to-door or fixed-point delivery of a single dose of azithromycin distribution to children 1-59 months of age via community health workers biannually. Treatment coverage, costs and cost-effectiveness, and feasibility and acceptability will be compared by arm.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Mortality, Child Health, Implementation
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
The AVENIR delivery trial is a two-armed, cluster-randomized trial in the Dosso region in Niger. 80 Communities will be randomized in a 1:1 allocation to either door-to-door delivery or fixed-point delivery of azithromycin to children 1-59 months of age.
Masking
None (Open Label)
Masking Description
In the delivery trial, participants, implementers, and outcome assessors will not be actively masked from the delivery approach given the nature of the intervention.
Allocation
Randomized
Enrollment
12057 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Azithro 1-59 fixed point
Arm Type
Active Comparator
Arm Description
Azithromycin distribution to children 1-59 months of age using a fixed-point delivery approach via existing community health workers
Arm Title
Azithro 1-59 door-to-door
Arm Type
Active Comparator
Arm Description
Azithromycin distribution to children 1-59 months of age using a door-to-door delivery approach via existing community health workers
Intervention Type
Drug
Intervention Name(s)
Azithromycin for Oral Suspension
Other Intervention Name(s)
Zithromax
Intervention Description
Azithromycin will be administered as a single dose in oral suspension form for children as follows:
Single-dose of 20mg/kg in children (up to the maximum adult dose of 1g)
For children 1 to <12 months of age, weight-based dosing will be used
For children 12 to 59 months of age, height-based dosing will be used via height-stick approximation as currently performed by Niger's trachoma program.
Primary Outcome Measure Information:
Title
Treatment Coverage
Description
Treatment coverage as defined by the number of doses of azithromycin administered in each community divided by the total eligible population
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Program Costs
Description
Program costs as captured by routine administrative data collection during the study period and by micro-costing activities
Time Frame
6 months
Title
Fidelity of intervention rollout
Description
Fidelity of intervention rollout reported as the percent of protocol steps with complete adherence by the field team
Time Frame
6 months
Title
Acceptability of intervention
Description
Participant and provider perception of acceptability of delivery approaches as measured by surveys conducted post-distribution
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
1 Month
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
At the community-level, eligibility includes:
Location in one of the 80 Dosso communities randomly selected for the delivery trial
Population 250 to 2,499*
Distance > 5 km from the district headquarters town
Verbal consent of community leader(s)
At the individual-level, eligibility includes:
Age 1-59 months
Primary residence in a study community
Verbal consent of caregiver/guardian for study participation
Weight ≥ 4 kg
Exclusion Criteria:
At the community-level, eligibility includes:
Inaccessible or unsafe for study team
"Quartier" designation on national census *Population size as estimated from the most recent national census or projections
At the individual-level, eligibility includes:
• Known allergy to macrolides
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Elodie Lebas, RN
Phone
5104232245
Email
elodie.lebas@ucsf.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Tom M Lietman, MD
Phone
415-502-2662
Email
tom.lietman@ucsf.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Tom M Lietman, MD
Organizational Affiliation
University of California, San Francisco
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Kieran S O'Brien, PhD, MPH
Organizational Affiliation
University of California, San Francisco
Official's Role
Principal Investigator
Facility Information:
Facility Name
Program National de Santé Oculaire
City
Niamey
Country
Niger
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Amza Abdou, MD
Email
dr.amzaabdou@gmail.com
First Name & Middle Initial & Last Name & Degree
Ahmed Arzika
Email
mamaneahmed@yahoo.fr
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
Data underlying outcomes publications will be made publicly available.
IPD Sharing Time Frame
Individual participant data will be made available after publication of the outcomes and will be made available indefinitely
IPD Sharing Access Criteria
Once made available, the data will be open access.
Learn more about this trial
Azithromycin for Child Survival in Niger: Delivery Trial
We'll reach out to this number within 24 hrs